Your shopping cart is currently empty

SU056 is a YB-1 inhibitor that interacts with YB-1, inhibiting downstream proteins and pathways. It can induce cell-cycle arrest, apoptosis, and inhibit cell migration in ovarian cancer cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $48 | In Stock | In Stock | |
| 10 mg | $78 | In Stock | In Stock | |
| 25 mg | $157 | In Stock | In Stock | |
| 50 mg | $249 | In Stock | In Stock |
| Description | SU056 is a YB-1 inhibitor that interacts with YB-1, inhibiting downstream proteins and pathways. It can induce cell-cycle arrest, apoptosis, and inhibit cell migration in ovarian cancer cells. |
| In vitro | SU056 ( 0-10 μ M, 48 hours) inhibits the growth of OVCAR3/4/5/8, SKOV3, and ID8 cells. SU056 (1 μ M, 5-8 days) inhibits colony formation in OVCAR-8 and ID8 cells in a dose-dependent manner. SU056 (1-5 μ M, 6 hours) blocks OVCAR8, SKOV3 and ID8 cells in sub G1 phase and G1 phase phase. SU056 (0-1 μ M, 12 hours) inhibits migration of OVCAR8, SKOV3 and ID8 cells. SU056 (0-5 μ M, 24 hours) induce apoptosis of OVCAR8, SKOV3, and ID8 cells. SU056 (1-5 μ M, 12 h) inhibits the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells. SU056 (0.1, 0.5, and 1 μ M. 48 hours) enhances the cytotoxic effect of paclitaxel (0.1, 0.5, and 1 nM) [1]. |
| In vivo | SU056 (20 mg/kg, intraperitoneal injection) inhibits tumor growth in mice implanted with ID8 cells. SU056 (10 mg/kg, intraperitoneal injection, daily) combined with paclitaxel (5 mg/kg, weekly, intraperitoneal injection) inhibits tumor growth in immunodeficient mice implanted with ovarian cancer cells (OVCAR8), and the effect is more significant than that of single administration [1]. |
| Molecular Weight | 369.34 |
| Formula | C20H16FNO5 |
| Cas No. | 2376580-08-2 |
| Smiles | OCCN1C2=C(C(c3cccc(F)c3)c3cc4OCOc4cc13)C(=O)OC2 |
| Relative Density. | 1.53 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 75 mg/mL (203.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.